Eli Lilly & Co. (NYSE: ELY) was downgraded to Equal Weight from Overweight at Morgan Stanley. Eli Lilly's arthritis drug was rejected by the FDA over safety concerns in treatment arms will require more data. Shares were indicated down 5% at $80.93, in a 52-week range of $64.18 to $86.72.